Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin With Nab-Paclitaxel in Advanced Squamous NSCLC
NCT02328105Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Objective Response Rate at 18 weeks. Started Dec 2014; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02328105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328105.